Myasthenia Gravis: Analytical Methods for the Determination in Biological Fluids of First-Line Therapeutic Agents Used in the Management of the Disease | Zendy

Chika J Mbah | Zendy

Open Access

Myasthenia Gravis: Analytical Methods for the Determination in Biological Fluids of First-Line Therapeutic Agents Used in the Management of the Disease

Author(s) -

Chika J Mbah

Publication year - 2019

Publication title -

cytokines their relation with mineral dust induced diseases

Language(s) - English

Resource type - Journals

ISSN - 2639-5649

DOI - 10.24966/ppp-5649/100010

Subject(s) - myasthenia gravis , acetylcholine receptor , neuromuscular junction , medicine , antibody , autoimmune disease , muscle weakness , nicotinic acetylcholine receptor , immunology , neuroscience , receptor , biology

Myasthenia Gravis (MG) an autoimmune disease is the prototype of neuromuscular junction disease caused by auto antibodies against the nicotinic Acetylcholine Receptor (AChR) located in the postsynaptic muscle endplate membrane [1,2]. The autoimmune disorder is characterized by weakness and fatigability of the voluntary muscle arising from the distortion and simplification of the postynaptic muscle membrane and consequent attachment of antibodies and complement to the membrane.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research